Hopes as COVID-19 treatment developer seeks approval for emergency use

Hopes as COVID-19 treatment developer seeks approval for emergency use

Covid-19 was one of the key factors U.S. voters considered in their decision to vote for the president for the next term.

As the count goes on to determine the White House winner, the battle against the novel coronavirus, which has killed over 230,000 Americans, is also still ongoing.

There was a lamp in the process and everyone around the world is expecting an effective solution to be announced sooner rather than later.

In the US, Regeneron Pharmaceuticals Inc. boosted the hopes by saying regulators are carefully analyzing the experimental antibody cocktail used to treat COVID-19. The group said they had high hopes the drug could soon be approved as an emergency Covid-19 treatment in the country.

It’s the same treatment that U.S. President Donald Trump was given after testing positive for COVID-19. The U.S. Food and Drug Administration began reviewing the treatment last month.

During the conference call to discuss the company’s earnings, Regeneron’s Chief Executive Officer Leonard Schleifer said they hope it will be a successful deal.

According to the company, clinical studies have shown that the treatment reduces the number of doctor visits for patients with mild to moderate cases. Based on the clinical studies, the Regeneron group hopes that the drug will be approved for emergency use in outpatients. The group that is said to benefit most from the drug.

According to Regeneration, about 80,000 doses of the drug could be ready by the end of this month and 300,000 doses by the end of January.

The company has been working to increase the production of the treatment. Even the 2020 research and development cost forecast has been raised from the original forecast of between $ 2.61 billion and $ 2.73 billion to between $ 2.75 billion and $ 2.82 billion.

To achieve the proposed dosage, it would also lead to higher costs in the first half of 2021. In the statement released last week, the company said that COVID-19 patients in advanced treatment are no longer enrolled in clinical trials, citing the potential safety signal and an unfavorable risk-benefit profile.

Regeneron’s scientific director, George Yancopoulos, said in theory that there weren’t many reasons why there could be a safety signal.

On Thursday, a data committee for a major UK study testing several other potential Covid-19 drugs, including Regeneron’s antibody treatment, said the study should include not only patients with mild symptoms but also patients with severe symptoms.

The committee said the decision came from data from more than 15,000 patients as well as available external information.

Regeneron’s Antibody treatment is not just the potential treatment to a large extent. There is also a vaccine developed by Oxford University, whose early studies have shown that it elicits an immune response in both young and older adults.

Also, with its homemade COVID-19 vaccine, India has announced that it could be ready by February.

Since its first confirmed in Wuhan Province, China, over 1.24 million people have died from the virus and over 49 million have tested positive.

Archie Fowler was born and raised in Cleveland. As a Reporter, Archie has contributed to several online publications including City Visitor Publications and Quantum Grafix. In regards to academics, Archie has got a Post Graduation Degree in Department Of Business from Cleveland State University. As a Reporter for Chroniclex Archie Covers World Topics.

Tel: +1 216-491-3453
Address: 98 W 117th St, Lakewood, OH 44107, United States

Share this post